OIPE
APR 25 2005
PATENT & TRADEMARK OFFICE

IFW 8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	10/780,905
Applicants	:	Daniel Paris et al.
Filed	:	February 18, 2004
Title	:	ANTI-ANGIOGENIC AND ANTI-TUMORAL PROPERTIES OF BETA AND GAMMA SECRETASE INHIBITORS
Group Art Unit	:	1654
Examiner	:	Marcela M. Cordero Garcia
Confirmation Number	:	7571
Customer Number	:	28289

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 CFR §§ 1.56, 1.97, and 1.98, the Applicants hereby submit this Information Disclosure Statement together with a completed Form PTO/SB/08A and one copy of the references, other than the United States patents, listed thereon.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 20, 2005.

Helen Gerace
(Name of Person Mailing Paper)

Signature — April 20, 2005 (Date)

04/26/2005 HMARZI1 00000005 10780905
01 FC:1806 180.00 OP


{W0179549.1}

The references identified on Form PTO/SB/08A were cited and discussed in the specification of the application.

Pursuant to 37 C.F.R. §§1.97(c) and 1.17(p) a fee of $180.00 is due for the submission of this Information Disclosure Statement, as it is being submitted after the mailing date of a first Office Action on the merits and before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311. The Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By 

Gwen R. Wood
Registration No. 51,027
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: 412-471-8815
Facsimile: 412-471-4094
E-mail: webblaw@webblaw.com

OIPE
APR 25 2005
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → [+]

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/780,905
Filing Date	February 18, 2004
First Named Inventor	Daniel Paris
Group Art Unit	1654
Examiner Name	Marcela M. Cordero Garcia
Attorney Docket Number	4303-040164

Sheet	1	of	1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T[2]
		CARMELIET, Peter, Mechanisms of angiogenesis and arteriogenesis, Nature Medicine, Vol. 6, No. 3, March 2000, pgs. 389-395.	
		VASSAR, Robert et al., β-Secretase Cleavage of Alzheimer's Amyloid Precursor..., Science Vol. 286, October 22, 1999, pgs. 735-741.	
		Hussain, Ishrut, Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase, Molecular and Cellular Neuroscience 14, 419-427 (1999).	
		YU, Gang et al., Journal of Biological Chemistry, Vol. 273 No. 26, Issue of June 26, pp 16470-16475, 1998.	
		CAPELL, Anja et al., The Proteolytic Fragments of the Alzheimer's Disease-associated..., Journal of Biological Chemistry, Vol. 273, No. 6, Issue of February 6, pp. 3205-3211, 1998.	
		WOLFE, Michael S., The Role of Presenilins in y-Secretase Activity, The Journal of Biological Chemistry, Vol. 276, No. 8, Issue of February 23, pp. 5413-5416, 2001.	
		De STROOPER, Bart et al., A presenilin-1-dependent y-secretase-like protease..., Nature, Vol. 398, April 8, 1999, pgs. 518-522.	
		ARTAVANIS-TSAKONAS, Spyros et al., Notch Signaling: Cell Fate Control and Signal Integration in Development, Science Magazine, April 30, 1999, Vol. 284, pgs. 770-776.	
		BROU, Christel, A Novel Proteolytic Clevage Involved in Notch Signaling: The Role of the Disintegrin-Metalloprotease TACE, Molecular Cell, Vol. 5, February 2000, pgs. 207-216.	
		GREENWALD, Iva, LIN-12/Notch signaling: lessons from worms and flies, Genes & Development, 12, pgs. 1751-1762.	
		CAO, Xinwei et al., A Transcriptively Active Complex of APP withFe65 and Histone Acetyltransferase Tip60, Science Magazine, Vol. 293, July 6, 2001, pgs. 115-120.	
		GUO, Qing et al., Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid β-peptide, Neurochemistry, Vol. 8 No. 1, December 20, 1996, pgs. 379-383.	
		LEISSRING, Malcolm A. et al., Capacitative Calcium Entry Deficits and Elevated Luminal Calcium Content in Mutant Presenilin-1 Knockin Mice, The Journal of Cell Biology, Vol. 149, No. 4, May 15, 2000, pgs. 793-797.	
		ZHONG, Tao P. et al., Gridlock signaliling pathway fashions the first embryonic artery, Nature, Vol. 414, November 8, 2001, pgs. 216-220.	
		HERREMAN, An et al, Presenilin 2 deficiency causes a mild pulmonary phenotype..., PNAS, 12, 1999, pgs. 11872-11877.	
		SHEN Jie, Skeletal and CNS Defects in Presenilin-1-Deficient Mice, Cell, Vol. 89, May 16, 1997, pgs. 629-639.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OIPE
APR 25 2005
PATENT & TRADEMARK OFFICE

PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/780,905
Filing Date	February 18, 2004
First Named Inventor	Daniel Paris
Art Unit	1654
Examiner Name	Marcela M. Cordero Garcia
Attorney Docket Number	4303-040164

Total Number of Pages in This Submission: too many to list

ENCLOSURES (Check all that apply)

- ☒ Fee Transmittal Form
 - ☒ Fee Attached
- ☐ Preliminary Amendment
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Documents
- ☐ Response to Missing Parts/ Incomplete Application
 - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawings (1 sheet attached to Amendment.)
- ☐ Licensing-related Papers
- ☐ Petition for Extension of Time
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s)_____
- ☐ After Allowance communication to Technology Center (TC)
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below) PTO/SB/08A (1 p. with references)

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Gwen R. Wood, Ph.D. Registration No. 51,027
Signature	Gwen R. Wood
Date	April 21, 2005

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Helen Gerace		
Signature	Helen Gerace	Date	April 21, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

APR 2 5 2005

PTO/SB/17 (12-04)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818)

FEE TRANSMITTAL
For FY 2005

[X] Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($)180.00

Complete if Known	
Application Number	10/780,905
Filing Date	February 18, 2004
First Named Inventor	Daniel Paris
Examiner Name	Marcela M. Cordero Garcia
Art Unit	1654
Attorney Docket No.	4303-040164

METHOD OF PAYMENT (check all that apply)

[X] Check [] Credit Card [] Money Order [] None [] Other (please identify): _____

[X] Deposit Account Deposit Account Number: 23-0650 Deposit Account Name _____

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

[] Charge fee(s) indicated below
[] Charge fee(s) indicated below, **except for the filing fee**
[X] Charge any additional fee(s) or underpayments of fee(s) Under 37 CFR 1.16 and 1.17
[X] Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee ($)	Fee ($)	Fee ($)	Fee ($)	Fee ($)	Fee ($)	Fees Paid ($)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee ($)	Small Entity Fee ($)
Each claim over 20 or, for Reissues, each claim over 20 and more than in the original patent	50	25
Each independent claim over 3 or, for Reissues, each independent claim more than in the original patent	200	100
Multiple dependent claims	360	180

Total Claims		Extra Claims	Fee ($)		Fee Paid ($)
49	- 49 or HP =	0	x _____	=	0

HP = highest number of total claims paid for, if greater than 20

Indep. Claims		Extra Claims	Fee ($)		Fee Paid ($)
3	- 3 or HP =	0	x _____	=	0

HP = highest number of independent claims paid for, if greater than 3

Multiple Dependent Claims	
Fee ($)	Fee Paid ($)
_____	0

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper, the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets		Extra Sheets		Number of each additional 50 or fraction thereof		Fee ($)		Fee Paid ($)
_____	- 100 =	_____	/ 50 =	_____	(round **up** to a whole number)	x _____	=	_____

4. OTHER FEE(S)

	Fee Paid ($)
Non-English Specification, $130 fee (no small entity discount)	
Other: **Information Disclosure Statement**	**$180.00**

SUBMITTED BY

Signature	Gwen R. Wood	Registration No. (Attorney/Agent) 51,027	Telephone 412-471-8815
Name (Print/Type)	Gwen R. Wood, Ph.D.		Date April 21, 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.